Log in
Enquire now
‌

US Patent 11623960 Dual-function antibodies targeting VEGFR2 and VEGFR3

Patent 11623960 was granted and assigned to National Health Research Institutes on April, 2023 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors

Contents

Is a
Patent
Patent
0

Patent attributes

Patent Applicant
‌
National Health Research Institutes
0
Current Assignee
‌
National Health Research Institutes
0
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
0
Patent Number
116239600
Patent Inventor Names
San-tai Shen0
Neng-yao Shih0
Yun-chang Chen0
Wen-chun Hung0
Ko-jiunn Liu0
Kuan-chung Hsiao0
Li-tzong Chen0
Date of Patent
April 11, 2023
0
Patent Application Number
169823610
Date Filed
March 20, 2019
0
Patent Primary Examiner
‌
Christine J. Saoud
0

An isolated antibody, comprising heavy chain complementary determining regions CDR1, CDR2, and CDR3 from a heavy chain variable region sequence having SEQ ID NO: 1 or 3; light chain complementary determining regions CDR1, CDR2, and CDR3 from a light chain variable region sequence having SEQ ID NO: 2 or 4; wherein the antibody binds specifically to both vascular endothelial growth factor receptor-2 (VEGFR2) and vascular endothelial growth factor receptor-3 (VEGFR3).

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like US Patent 11623960 Dual-function antibodies targeting VEGFR2 and VEGFR3

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.